2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Incyte Corporation company profile · business segments · history · financial snapshot · S&P 500 rank #367 · Incyte 業務歷史財務與標普500地位
SNAPSHOT
| Ticker | INCY |
| Company | Incyte Corporation |
| GICS sector / industry | Health Care (XLV) / Biotechnology |
| S&P 500 rank (by weight) | #367 · 0.03% (Nov 4, 2026) |
| Sector rank | #46 of 60 in Health Care (Nov 4, 2026) |
| Headquarters | Wilmington, Delaware |
| Founded | 1991 |
| CEO | Bill Meury (President and CEO, per February 2026 results release) |
| Employees | 2,844 full-time employees |
| Market cap | $23.97B (Nov 4, 2026) |
| SEC filings | EDGAR — CIK 0000879169 |
WHAT IT DOES
Incyte Corporation is a global biopharmaceutical company headquartered in Wilmington, Delaware, focused on hematology and oncology plus inflammation and autoimmunity. Founded in 1991, it discovers, develops and commercializes proprietary therapeutics, selling in the United States, Europe and Japan through its own operations and partnerships including Novartis and Eli Lilly.
Its one-line model: turn JAK-pathway and targeted science into marketed medicines, then reinvest product cash flow into a pipeline spanning hematology, oncology and dermatology. The flagship is Jakafi (ruxolitinib) for myelofibrosis, polycythemia vera and graft-versus-host disease; the growth engine is the non-Jakafi portfolio led by Opzelura (ruxolitinib) cream.
Fiscal 2025 total revenue was $5.14B, up 21%, of which net product revenue was $4.35B, up 20%. The non-Jakafi core grew 53% to $1.26B in 2025, with Opzelura, Niktimvo (axatilimab-csfr) in chronic graft-versus-host disease and Monjuvi (tafasitamab) among the largest contributors.
BUSINESS SEGMENTS
| Jakafi (ruxolitinib) | Flagship JAK inhibitor for myelofibrosis, polycythemia vera and graft-versus-host disease; partnered with Novartis outside the United States and the largest single product. |
| Opzelura (ruxolitinib) cream | Topical JAK inhibitor for atopic dermatitis and vitiligo; a core driver of the non-Jakafi growth story, including a U.S. approval for pediatric eczema patients aged 2–11. |
| Other Hematology / Oncology | Niktimvo in chronic graft-versus-host disease, Monjuvi in relapsed or refractory diffuse large B-cell lymphoma, plus Pemazyre and Iclusig; together with Opzelura, the ex-Jakafi core reached $1.26B in 2025, up 53%. |
| Milestones, royalties & other revenue | Collaboration milestones and contract revenue plus royalties — the difference between $5.14B total revenue and $4.35B net product revenue in 2025. |
HISTORY
| Year | Milestone |
|---|---|
| 1991 | Incyte is founded in Wilmington, Delaware, as a drug-discovery company. |
| 2011 | Jakafi becomes the anchor product of the company (ruxolitinib, developed with Novartis as partner outside the United States). |
| 2014 | Hervé Hoppenot serves as chief executive from 2014, leading the Jakafi commercial era. |
| 2021 | Opzelura cream launches, opening the dermatology franchise alongside hematology and oncology. |
| 2025 | Total revenue reaches $5.14B, up 21%; non-Jakafi products grow 53% to $1.26B, and Bill Meury is president and CEO in the February 2026 results release. |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT
| Total revenue | $5.14B (FY2025 total revenue) |
| Operating income | $1.51B (FY2025 operating income) |
| Net income | $1.29B (FY2025 net income) |
| Diluted EPS | $6.59 (FY2025 diluted EPS) |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Incyte is a small-weight health care constituent: rank #367 by weight at 0.03% as of Nov 4, 2026, and #46 in Health Care. It is the index's mid-cap biotech transition story — a single-franchise company proving, in real time, that its second act can outgrow its first before the patent clock runs out.
SOURCES & METHODOLOGY
| Financials, segments, headquarters | Incyte Corporation fiscal 2025 Form 10-K data (year ended December 31, 2025) and fourth-quarter/full-year 2025 results release; headquarters, CEO and products via the Form 10-K and company reporting |
| Index weight & ranks | Slickcharts S&P 500 weights, fetched Nov 4, 2026; sector membership per Wikipedia List of S&P 500 companies (GICS) |
| Market cap | $23.97B (Slickcharts, Nov 4, 2026) |
| Logo | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. |
| Chart | SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 股票代號 | INCY |
| 公司 | Incyte Corporation(Incyte) |
| GICS 板塊/行業 | 醫療保健(XLV)/生物科技 |
| 標普500排名(按權重) | #367 · 0.03%(Nov 4, 2026) |
| 板塊內排名 | 醫療保健 #46(共 60 家)(Nov 4, 2026) |
| 總部 | 美國特拉華州威爾明頓 |
| 成立 | 1991年 |
| 執行長 | Bill Meury(總裁兼執行長,按 2026 年 2 月業績公布) |
| 員工 | 2,844 名全職員工 |
| 市值 | $23.97B(Nov 4, 2026) |
| SEC 申報 | EDGAR — CIK 0000879169 |
業務概覽
Incyte Corporation 是全球生物製藥公司,總部位於美國特拉華州威爾明頓,專注血液學與腫瘤學以及炎症與自身免疫疾病。公司成立於 1991 年,自行發現、開發並銷售專利藥物,透過自身業務及與 Novartis、Eli Lilly 等夥伴的合作,在美國、歐洲與日本銷售。
其一句話商業模式是:把 JAK 通路與靶向科學轉化為上市藥物,再把產品現金流再投資於橫跨血液學、腫瘤學與皮膚科的研發管線。旗艦產品為 Jakafi(ruxolitinib),用於骨髓纖維化、真性紅細胞增多症與移植物抗宿主病;增長引擎是以 Opzelura(ruxolitinib)乳膏為首的非 Jakafi 產品組合。
2025 財年總收入 51.41 億美元,增長 21%,其中淨產品收入 43.53 億美元,增長 20%。非 Jakafi 核心業務 2025 年增長 53% 至 12.63 億美元,Opzelura、治療慢性移植物抗宿主病的 Niktimvo(axatilimab-csfr)與 Monjuvi(tafasitamab)是增長最大的產品。
業務板塊
| Jakafi(ruxolitinib) | 旗艦 JAK 抑制劑,用於骨髓纖維化、真性紅細胞增多症與移植物抗宿主病;美國以外與 Novartis 合作,是最大的單一產品。 |
| Opzelura(ruxolitinib)乳膏 | 外用 JAK 抑制劑,用於特應性皮炎與白癜風;是非 Jakafi 增長故事的核心動力,包括美國批准用於 2–11 歲兒童濕疹患者。 |
| 其他血液/腫瘤產品 | 治療慢性移植物抗宿主病的 Niktimvo、治療復發或難治性瀰漫性大 B 細胞淋巴瘤的 Monjuvi,以及 Pemazyre 與 Iclusig;連同 Opzelura,非 Jakafi 核心業務 2025 年達 12.63 億美元,增長 53%。 |
| 里程碑、特許權使用費及其他收入 | 合作里程碑與合約收入及特許權使用費——即 2025 年總收入 51.41 億美元與淨產品收入 43.53 億美元之間的差額。 |
歷史
| 年份 | 里程碑 |
|---|---|
| 1991 | Incyte 在特拉華州威爾明頓成立為藥物發現公司。 |
| 2011 | Jakafi 成為公司的支柱產品(ruxolitinib,美國以外由 Novartis 合作開發)。 |
| 2014 | Hervé Hoppenot 自 2014 年起出任執行長,領導 Jakafi 的商業化時代。 |
| 2021 | Opzelura 乳膏上市,在血液學與腫瘤學之外開闢皮膚科業務。 |
| 2025 | 總收入達 51.41 億美元,增長 21%;非 Jakafi 產品增長 53% 至 12.63 億美元,Bill Meury 在 2026 年 2 月業績公布中為總裁兼執行長。 |
競爭地位
財務快照
| 總收入 | $5.14B(FY2025 總收入) |
| 營業利潤 | $1.51B(FY2025 營業利潤) |
| 淨利潤 | $1.29B(FY2025 淨利潤) |
| 稀釋 EPS | $6.59(FY2025 稀釋 EPS) |
主要風險
對標普500的重要性
Incyte 是權重較小的醫療保健成分股:按權重排名 #367,權重 0.03%(以 2026 年 11 月 4 日為準),醫療保健板塊內排名 #46。它是指數中的中型生物科技轉型故事——一家單一業務公司正在實時證明,其第二幕可以在專利時鐘走完之前超越第一幕。
來源與方法
| 財務、板塊、總部 | Incyte Corporation 2025 財年 Form 10-K 數據(截至 2025 年 12 月 31 日)及 2025 年第四季與全年業績公布;總部、執行長與產品經 Form 10-K 及公司披露 |
| 指數權重與排名 | Slickcharts 標普 500 權重,Nov 4, 2026 抓取;板塊歸屬按維基百科標普 500 成分股名單(GICS) |
| 市值 | $23.97B(Slickcharts,Nov 4, 2026) |
| Logo | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 |
| 股價圖 | SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月線(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-11-03 21:47 · updated 2026-11-14 23:39 · rev 7